US Stock MarketDetailed Quotes
ORIC Oric Pharmaceuticals
- 8.070
- +0.400+5.22%
Close Apr 26 16:00 ET
- 8.250
- +0.180+2.23%
Post 16:33 ET
544.10MMarket Cap-4117P/E (TTM)
8.130High7.730Low401.57KVolume7.730Open7.670Pre Close3.21MTurnover1.08%Turnover RatioLossP/E (Static)67.42MShares16.65052wk High2.43P/B299.63MFloat Cap4.90052wk Low--Dividend TTM37.13MShs Float40.810Historical High--Div YieldTTM5.22%Amplitude2.360Historical Low8.004Avg Price1Lot Size
Oric Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -14.03%-85.69M | -58.33%-24.27M | -1.68%-19.65M | -18.95%-21.15M | 9.20%-20.63M | -26.20%-75.14M | 5.86%-15.33M | -59.12%-19.32M | -9.63%-17.78M | -52.46%-22.72M |
| Net income from continuing operations | -12.99%-100.7M | -35.89%-28.33M | -2.61%-25.48M | -13.10%-22.94M | -3.39%-23.95M | -13.22%-89.12M | 8.45%-20.85M | -34.75%-24.83M | 3.44%-20.29M | -40.28%-23.16M |
| Operating gains losses | -45.00%22K | --13K | --0 | ---- | ---- | 1,900.00%40K | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 6.83%1.03M | 6.48%263K | 16.29%257K | 4.86%259K | 0.80%253K | 7.69%966K | 7.86%247K | 1.84%221K | 11.26%247K | 9.61%251K |
| Change In working capital | 1,200.67%4.9M | -27.09%1.98M | 53.66%3.63M | 40.54%-1.03M | 108.19%311K | -110.93%-445K | 4.21%2.72M | 1.07%2.37M | -286.85%-1.73M | -110.24%-3.8M |
| -Change in prepaid assets | 57.28%1.62M | -21.30%1.01M | -114.85%-277K | 86.61%-211K | 305.78%1.1M | -9.81%1.03M | 867.42%1.28M | 165.29%1.87M | -40.09%-1.58M | -137.43%-536K |
| -Change in payables and accrued expense | 322.24%3.28M | -32.20%979K | 682.20%3.91M | -418.99%-820K | 75.71%-792K | -150.32%-1.48M | -41.75%1.44M | -69.46%500K | -107.70%-158K | -0.71%-3.26M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -14.03%-85.69M | -58.33%-24.27M | -1.68%-19.65M | -18.95%-21.15M | 9.20%-20.63M | -26.20%-75.14M | 5.86%-15.33M | -59.12%-19.32M | -9.63%-17.78M | -52.46%-22.72M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 60.27%-43.4M | -25.93%20.96M | -8,342.48%-57.83M | 58.20%-19.31M | 114.09%12.78M | -168.95%-109.25M | 7,962.68%28.3M | -101.95%-685K | -156.10%-46.2M | -323.04%-90.66M |
| Net PPE purchase and sale | 59.14%-849K | 80.14%-57K | 80.80%-77K | 39.28%-405K | 57.12%-310K | -121.30%-2.08M | 26.22%-287K | -72.10%-401K | -394.07%-667K | -297.25%-723K |
| Net investment purchase and sale | 60.29%-42.55M | -26.47%21.02M | -20,235.92%-57.75M | 58.48%-18.91M | 114.55%13.09M | -167.24%-107.17M | 3,763.11%28.59M | -100.80%-284K | -155.20%-45.54M | -320.28%-89.94M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 60.27%-43.4M | -25.93%20.96M | -8,342.48%-57.83M | 58.20%-19.31M | 114.09%12.78M | -168.95%-109.25M | 7,962.68%28.3M | -101.95%-685K | -156.10%-46.2M | -323.04%-90.66M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 239.58%85.66M | -98.17%453K | 3,000.00%31K | 20,423.86%85.17M | 0 | -48.66%25.23M | 2,949.57%24.79M | -100.00%1K | 247.69%415K | 0.00%16K |
| Net common stock issuance | 240.00%85M | -99.10%226K | --0 | ---- | ---- | -50.00%25M | --25M | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | 41.83%885K | 136.46%454K | 3,000.00%31K | -3.61%400K | --0 | -36.71%624K | -76.38%192K | -98.99%1K | 615.52%415K | 0.00%16K |
| Net other financing activities | 43.11%-227K | ---- | ---- | ---- | ---- | 78.46%-399K | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 239.58%85.66M | -98.17%453K | 3,000.00%31K | 20,423.86%85.17M | --0 | -48.66%25.23M | 2,949.57%24.79M | -100.00%1K | 247.69%415K | 0.00%16K |
| Net cash flow | ||||||||||
| Beginning cash position | -70.28%67.31M | -9.53%26.73M | 110.25%104.17M | -47.43%59.46M | -70.28%67.31M | 188.70%226.47M | -87.77%29.54M | -70.87%49.55M | 8.54%113.11M | 188.70%226.47M |
| Current changes in cash | 72.71%-43.43M | -107.56%-2.85M | -287.15%-77.45M | 170.35%44.72M | 93.08%-7.85M | -207.52%-159.17M | 349.76%37.76M | -127.97%-20M | -196.50%-63.56M | -540.04%-113.36M |
| End cash Position | -64.53%23.88M | -64.53%23.88M | -9.53%26.73M | 110.25%104.17M | -47.43%59.46M | -70.28%67.31M | -70.28%67.31M | -87.77%29.54M | -70.87%49.55M | 8.54%113.11M |
| Free cash flow | -12.06%-86.54M | -55.78%-24.33M | -0.01%-19.72M | -16.85%-21.55M | 10.68%-20.94M | -27.68%-77.22M | 6.34%-15.62M | -59.36%-19.72M | -12.81%-18.44M | -55.41%-23.44M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg